Menu Search
Equities

Conmed Corp

CNMD:NYQ

Conmed Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)74.90
  • Today's Change3.19 / 4.45%
  • Shares traded155.94k
  • 1 Year change-30.58%
  • Beta1.4620
Data delayed at least 15 minutes, as of Nov 22 2024 19:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform4
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Conmed Corp have a median target of 80.00, with a high estimate of 102.00 and a low estimate of 72.00. The median estimate represents a 11.56% increase from the last price of 71.71.
High42.2%102.00
Med11.6%80.00
Low0.4%72.00

Dividends in USD

In 2023, Conmed Corp reported a dividend of 0.80 USD, equaling last years dividend. The 2 analysts covering the company expect dividends of 0.80 USD for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in USD

On Oct 30, 2024, Conmed Corp reported 3rd quarter 2024 earnings of 1.05 per share. This result exceeded the 0.99 consensus of the 8 analysts covering the company and exceeded last year's 3rd quarter results by 16.67%.
The next earnings announcement is expected on Jan 29, 2025.
Average growth rate+5.87%
Conmed Corp reported annual 2023 earnings of 3.45 per share on Jan 08, 2024.
Average growth rate+10.64%
More ▼

Revenue history & estimates in USD

CONMED Corporation had 3rd quarter 2024 revenues of 316.70m. This missed the 318.13m consensus estimate of the 8 analysts following the company. This was 7.19% above the prior year's 3rd quarter results.
Average growth rate+1.14%
CONMED Corporation had revenues for the full year 2023 of 1.24bn. This was 19.06% above the prior year's results.
Average growth rate+7.50%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.